

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 478-P-10-PCT	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/US99/19449	International filing date (<i>day/month/year</i>) 30 AUGUST 1999	(Earliest) Priority Date (<i>day/month/year</i>) NONE
Applicant JARIWALLA, RAXIT J		

This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of 2 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. ☐ Certain claims were found unsearchable (See Box I).
2. ☐ Unity of invention is lacking (See Box II).
3. ☐ The international application contains disclosure of a nucleotide and/or amino acid sequence listing and the international search was carried out on the basis of the sequence listing

☐ filed with the international application.
☐ furnished by the applicant separately from the international application,

☐ but not accompanied by a statement to the effect that it did not include matter going beyond the disclosure in the international application as filed.

☐ transcribed by this Authority.
4. With regard to the title,

☒ the text is approved as submitted by the applicant.
☐ the text has been established by this Authority to read as follows:
5. With regard to the abstract,

☒ the text is approved as submitted by the applicant.
☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.
6. The figure of the drawings to be published with the abstract is:
 Figure No. _____

☐ as suggested by the applicant. ☐ None of the figures.
☐ because the applicant failed to suggest a figure.
☐ because this figure better characterizes the invention.

RECEIVED

NOV 09 2001

TECH CENTER 1600/2981

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 March 2001 (08.03.2001)

PCT

(10) International Publication Number
WO 01/15692 A1

- (51) International Patent Classification⁷: A61K 31/34 (81) Designated States (*national*): AU, CA, CN, IS, JP, KP, KR, MX, NO, NZ, SG, TR, US.
- (21) International Application Number: PCT/US99/19449
- (22) International Filing Date: 30 August 1999 (30.08.1999) (84) Designated States (*regional*): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
- (25) Filing Language: English
- (26) Publication Language: English Published:
— with international search report
- (71) Applicant (*for all designated States except US*): OXYCAL LABORATORIES, INC. [US/US]; 533 Madison Avenue, Prescott, AZ 86301 (US). (48) Date of publication of this corrected version:
11 October 2001
- (72) Inventor; and
- (75) Inventor/Applicant (*for US only*): JARIWALLA, Raxit, J. [US/US]; 19120 Vineyard Drive, Saratoga, CA 95070 (US). (15) Information about Correction:
see PCT Gazette No. 41/2001 of 11 October 2001, Section II
- (74) Agents: DRUMMOND, William, H. et al.; Drummond & Duckworth, Suite 500, 4590 MacArthur Boulevard, Newport Beach, CA 92660 (US). *For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: METHODS AND COMPOSITIONS FOR SELECTIVE CANCER CHEMOTHERAPY

(57) Abstract: A selective chemotherapy method includes the step of contacting tumor cells with a mineral ascorbate/vitamin C metabolite composition. A chemotherapeutic composition comprises the mineral ascorbate/vitamin C metabolite composition in a pharmacologically acceptable intravenous carrier.

WO 01/15692 A1



09/830912

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 March 2001 (08.03.2001)

PCT

(10) International Publication Number
WO 01/15692 A1

- (51) International Patent Classification⁷: **A61K 31/34** (74) Agents: **DRUMMOND, William, H. et al.**; Drummond & Duckworth, Suite 500, 4590 MacArthur Boulevard, Newport Beach, CA 92660 (US).
- (21) International Application Number: **PCT/US99/19449**
- (22) International Filing Date: **30 August 1999 (30.08.1999)** (81) Designated States (*national*): **AU, CA, CN, IS, JP, KP, MX, NO, NZ, SG, TR, US.**
- (25) Filing Language: **English**
- (26) Publication Language: **English** (84) Designated States (*regional*): **European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).**
- (71) Applicant (*for all designated States except US*): **OXYCAL LABORATORIES, INC.** [US/US]; 533 Madison Avenue, Prescott, AZ 86301 (US).
- Published:
— *With international search report.*
- (72) Inventor; and
- (75) Inventor/Applicant (*for US only*): **JARIWALLA, Raxit, J.** [US/US]; 19120 Vineyard Drive, Saratoga, CA 95070 (US).
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 01/15692 A1

(54) Title: **METHODS AND COMPOSITIONS FOR SELECTIVE CANCER CHEMOTHERAPY**

(57) Abstract: A selective chemotherapy method includes the step of contacting tumor cells with a mineral ascorbate/vitamin C metabolite composition. A chemotherapeutic composition comprises the mineral ascorbate/vitamin C metabolite composition in a pharmacologically acceptable intravenous carrier.

**METHODS AND COMPOSITIONS
FOR SELECTIVE CANCER CHEMOTHERAPY**

Field of the Invention

5 This invention relates to tumor-cytotoxic
chemotherapeutic methods.

 In another aspect the invention relates to tumor-
cytotoxic chemotherapeutic compositions.

 More particularly the invention concerns tumor-
10 cytotoxic chemotherapeutic methods and compositions for
treating cancers in a human host.

Background of the Invention

 Tumor cytotoxic chemotherapeutic agents preferentially
induce death (apoptosis) of malignant cells. Because of
15 similarities between normal and malignant cells, both being
born of the same host, a chemotherapeutic dose which induces
apoptosis of tumor cells can also be toxic to normal cells.
In order to effect a remission, the tumor-cytotoxic agent
must often push the limits of acceptable side effects.
20 Ideally, the tumor-cytotoxic agent should be "selective",
i.e., there should be a large gap between the lower dose

required to induce tumor cell death, for efficacy as a tumor-cytotoxic chemotherapeutic agent, and the higher dose which is toxic to the patient's normal cells.

The adverse side-effects of chemotherapy may include hair loss, nausea and vomiting, cardiac toxicity and secondary cancers. One of the most common side-effect toxic manifestations of many cytotoxic agents is bone marrow suppression, which can lead to immune suppression and hematopoietic dysfunctions. Because infectious complications are one of the major causes of death in cancer patients, it would be highly desirable to provide non-toxic tumor-cytotoxic chemotherapeutic compositions and methods without immunosuppressive side effects.

Compounds having vitamin C activity, e.g., ascorbic acid and ascorbate derivatives, are not immunosuppressive, but are effective intravenous cytotoxic chemotherapeutic agents against a wide variety of cancers. Riordan et al., *Medical Hypotheses*, 1995, 44, 207-213. However, there is no vitamin C storage mechanism in human tissues and it is all metabolized and/or excreted. Further, because of gastrointestinal complications, it is difficult to establish and maintain high serum levels of vitamin C by oral

administration of ascorbic acid. Thus, it is generally considered necessary to administer ascorbic acid intravenously in order to establish and maintain plasma levels sufficiently high to achieve cytotoxicity.

5 Therefore, it would be extremely advantageous to provide tumor chemotherapeutic compositions, containing forms of vitamin C other than ascorbic acid, which can be orally administered in doses sufficiently high to establish and maintain a tumor cytotoxic level of serum vitamin C.

10 However, because even vitamin C can be toxic to normal human cells if the plasma concentration is sufficiently high, it would also be highly desirable to provide selective vitamin C tumor chemotherapeutic compositions in oral or intravenous dosage forms, which achieve tumor cell apoptosis
15 at lower plasma concentrations than those required for ascorbic acid to induce tumor cell apoptosis. Because the tumor cytotoxic concentration of vitamin C administered from such dosage forms would be lower, it would be more feasible to establish and maintain a chemotherapeutically effective
20 plasma concentration at a level which would be below the vitamin C plasma apoptosis level for normal cells.

The Prior Art

As reviewed by Cameron et al. (Cancer Res., 39:663-81 (1979)) some clinical trials have shown significant increases in survival times of cancer patients receiving vitamin C.

Elvin et al. (Eur. J. Cancer Clin. Oncol. 17(7):759-65 (1981)) reported that adducts of ascorbic acid with aldehydes such as methylglyoxal and acetylacrolein inhibit growth of Ehrlich ascites carcinoma in mice.

EP-A-0086544 proposes uses of ketals and acetals of ascorbic acid as angiogenesis-inhibiting agents. (Angiogenesis refers to the process of new blood vessel development, the proliferation of new blood vessels being involved in tumor growth.)

EP-A-0148094 and U.S. Patent 5,032,610 propose that orally administered or intravenously administered 5,6-O-benzylidene-L-ascorbic acid and salts thereof and mixtures thereof with L-ascorbic acid and salts thereof exhibit anti-cancer properties.

Concomitant administration of 3-amino-1,2,4-triazole enhances the cytotoxicity of ascorbic acid to Ehrlich ascites tumor cells and the addition of vitamin K3 (menadione sodium bisulfite) appears to increase preferential tumor cytotoxicity of ascorbic acid. Benande et al., *Oncology*, 23:33-43 (1969).

Also, prior workers have shown that catalytic concentrations of Cu^{2+} increased the preferential toxicity of ascorbic acid for several malignant melanoma cell lines, including four human-derived lines. Bram et al., *Nature* 284: 629-631(1980).

Several leukemic, pre-leukemic and myeloma progenitor cells derived from human patients were reported to be sensitive to ascorbic acid concentrations attainable *in vivo*, without any toxicity to normal hemopoietic cells. Park et al., Cancer Res. 4:1062-65 (1980); Am.J.Clin.Nutr. 54:1241S-46S (1991).

Description of the Drawings

Fig. 1 is a bar graph which illustrates the apoptosis of various tumor cell-types by the "mineral ascorbate plus metabolites" composition employed in the practice of the preferred invention, as illustrated by Test 1.

Fig. 2 is a similar bar graph which illustrates the selectivity of apoptosis of various tumor cell-types over normal cells by the "mineral ascorbate plus metabolites" composition employed in the preferred practice of the invention, as illustrated by Test 1.

Brief Description of the Invention

The chemotherapy method of the present invention includes the step of contacting tumor cells with a

composition comprising a plasma-soluble mineral ascorbate and one or more vitamin C metabolites selected from the group consisting of aldonic acids, the aldono-lactones, aldono-lactides and non-toxic metal salts of aldonic acids, dehydroascorbic acid, threose, erythreose, 4-hydroxy-5-methyl-3(2H)-furanone, 3-hydroxykojic acid and 5-hydroxymaltol.

The novel chemotherapeutic compositions of the invention, which are useful in practicing the method of the invention, comprises the components of such chemotherapeutic compositions in a pharmacologically acceptable intravenous carrier.

The Preferred Embodiments of the Invention

The components of the above-described chemotherapeutic composition are simply mixed together in appropriate proportions. The exact proportions are not highly critical. Operable and optimum proportions can be determined and varied within limits which can be determined without undue experimentation by those skilled in the art, e.g., by employing *in vitro* tests such as those described below. Alternatively, in accordance with the presently preferred

embodiment of the invention, suitable mineral ascorbate-metabolite compositions, containing these components in appropriate proportions, are commercially available under the registered trademark ESTER-C® from Inter-Cal Corporation, Prescott, Arizona, USA. These compositions are further described in United States Patents 4,822,816; 4,968,716; and 5,070,085, incorporated herein by reference.

The cytotoxically effective vitamin C plasma concentration provided by the chemotherapeutic methods and compositions of the invention will vary according to the specific type of tumor cells being treated and can be determined by *in vitro* tests such as those described below, animal tests and human *in vivo* trials, in accordance with art-recognized techniques.

The chemotherapeutic compositions of the invention are formulated for intravenous administration by inclusion of the mineral ascorbate and vitamin C metabolite components in a pharmaceutically acceptable intravenous carrier, i.e., a sterile, non-toxic solution of the components in a carrier, formulated to provide appropriate osmolality, pH, etc., in accordance with art-recognized techniques. For example, Ringer's Lactate is an appropriate intravenous carrier.

The concentration of vitamin C in the intravenous carrier can be varied within wide limits to suit the requirements of treatment. For example, when it is desired to establish an ascorbic acid equivalent plasma concentration in the range 150-200 mg/dL, an appropriate dosage for an 8-hour, 1000 cc infusion is 100-150 mg of ascorbate provided by the mineral salt. It may be required to repeat such infusions several times before reaching and maintaining the desired plasma concentration, depending on the capacity of the patient's system for ascorbate destruction, elimination or excretion.

It is also possible to employ oral dosage forms containing the mineral ascorbate/vitamin C metabolite compositions to establish initial plasma concentrations of these compositions which are effective to induce apoptosis in some forms of tumors. According to my present information, at oral dosages in the range of approximately 12-15 grams of ascorbate per day, a plasma level (AA equivalent) of approximately 5 mg/dl is attainable, which is sufficient to induce selective apoptosis of melanoma and hepatoma cells.

Moreover, once a selective tumor apoptosis-inducing plasma concentration is obtained by intravenous administration, that concentration can be maintained by administration of oral dosage forms or by a combination of oral and intravenous administration.

EXAMPLES

The following examples are presented for the purpose of illustrating the practice of the invention and identifying the presently preferred embodiments thereof to persons skilled in the art, and are not to be construed as limitations on the scope of the invention.

Several tumor cell lines and corresponding normal non-malignant cell lines are tested for apoptosis by Ester-C® (Calcium Ascorbate plus metabolites) versus four other test compositions, calcium ascorbate (CA) alone, calcium threonate (CT) alone and calcium ascorbate plus calcium threonate (CA+CT) and sterile water (SH₂O).

EXAMPLE 1

Test Procedures

The cell lines are:

Malme-3M Melanoma, Human (ATCC No. HTB-64)

5 Malme-3 Normal Human Skin Fibroblasts (ATCC No. HTB-

 102)

SK-Hep-1 Liver adenocarcinoma, Human (ATCC No. HTB-52)

WRL Normal Human Liver Cells (ATCC No. CL-98)

SK-N-MC Neuroblastoma, Human (ATCC No. HTB-10)

10 T-84 Colon Carcinoma, Human (ATCC No. CCL-248)

Stock cells are grown in the growth media, as follows:

	<u>Cell Line</u>	<u>Growth Media</u>
5	SK-Hep-1, SK-N-MC and WRL 88	Eagle's Minimal Essential Medium in Earle's salts supplemented with 2mM L- glutamine, 1mM sodium pyruvate, 10% fetal bovine serum (FBS) and antibiotics (penicillin, streptomycin, 10 amphotericin B)
	Malme-3 and Malme 3-M	McCoy's medium with L- glutamine, 15% FBS and antibiotics
15	T-84	1:1 mixture of Dulbecco's modified MEM and Ham's F-12 medium with L-Glutamine, pyridoxal hydrochloride, 25 mM Hepes plus 5% FBS and 20 antibiotics

All cultures are maintained at 37 C in a humidified
atmosphere of 5%CO₂/95% air. Media and culture reagents are
obtained from Life Technologies (Gibco/BRL, Long Island,
NY). FBS is obtained from Hyclone Labs (Logan, UT).

25 Test materials are obtained from Inter-Cal Corporation
(Prescott, AZ), as follows:

Test 1	Ester-C® Mineral Ascorbate (see below)
Test 2	Calcium Ascorbate (USP Grade), 82.15% ascorbic acid (AA) equivalent
Test 3	Calcium Threonate, 87.08% L-threonic acid (TA) equivalent
Test 4	Calcium Ascorbate (U.S.P.) + Calcium U.S.P., 81.21% AA, 1% TA equivalent
Test 5	Ascorbic Acid

10 The Test 1 material contains the following by laboratory analysis:

Calcium Ascorbate	78.4% AA equivalent
Calcium Threonate	.9% TA equivalent
Other AA Metabolites ¹	10.4% AA equivalent
Water of Crystallization	Balance

15 Ascorbic Acid (tissue culture grade) is obtained from Sigma Chemical Co. (St. Louis, MO). Control compositions consist of growth medium, Ringer's Solution or sterile water, as appropriate.

¹ aldonic acids, the aldono-lactones, aldono-lactides and non-toxic metal salts of aldonic acids, dehydroascorbic acid, threose, erythrose, 4-hydroxy-5-methyl-3(2H)-furanone, 3-hydroxykojic acid and 5-hydroxymaltol.

All working solutions are prepared from master stocks immediately before use. A 60 mM master stock solution of AA is prepared in serum-free growth medium and stored at -15 C. Working solutions are made from 10X strength stock solutions by dilution in growth medium. A 30mM (1gm/%) stock of calcium threonate is made in Ringer's solution (Fay and Verlangieri, Life Sciences, 49:1377 (1991)) or warm sterile water. Working solutions are made as 1X strength stock (in Ringer's solution) or as 10X stock (in H_2O), depending on the nature of the treatment, i.e., short-term versus continuous, (see below).

For evaluation of the Test 1 material, 1-1.3% master stock solution of the Test material is prepared in warm sterile water. Working stock solutions (10X strength) are made in sterile water immediately before use. For comparative evaluation, stock solutions of Test 2 and Test 4 solutions are prepared in sterile water, normalized to contain AA equivalents identical to the Test 1 stock. These stocks are stored at room temperature for use in evaluations.

Example 2**Treatment of Cell Cultures with
Ascorbic Acid and/or Calcium Threonate**

0.25-1.0 $\times 10^5$ cells of tumor-derived or normal liver
5 cell lines are seeded and cultured in individual wells of a
24-well cluster plate in the presence of increasing
concentrations of freshly prepared supplement consisting of
ascorbic acid (AA) or calcium ascorbate (CA). Cultures are
re-fed periodically with additions of respective
10 supplements, with or without medium change as indicated.
Controls consist of cells receiving growth medium without
added supplement.

For treatment with calcium threonate (CT), cells are
allowed to attach by overnight incubation. The following
15 day, threonate treatment is initiated using one of two
protocols.

In one protocol (short exposure), monolayers are
washed and exposed directly to 1 mL/well of 7.5-30 mM
threonate (prepared in Ringer's solution) for brief periods
20 at 37 C as described by Fay and Verlangieri (referenced
above). Controls are exposed to 1 mL/well of Ringer's
solution alone for similar intervals. After exposure, the

solution is removed and replaced by growth medium.

In the other protocol (continuous exposure), one-tenth volume of 10X strength threonate (prepared in sterile water) is added to the culture medium and the incubation continued at 37 C. This same treatment is repeated by daily additions of fresh working solution.

Example 3
Treatment of Cell Cultures With
Ascorbic Acid Plus Calcium Threonate

Cells are treated with calcium threonate (CT), as in Example 2, for sixty minutes at 37C followed by addition of ascorbic acid (AA) in Ringer's solution and continuous incubation for thirty minutes. At the end of the treatment period, the solution is removed and replaced by 1 mL/well of growth medium.

Example 4

Treatment of Cell Cultures with Test 1
(Ester-C® Calcium Ascorbate Plus Metabolites) and
Test 4 (Calcium Ascorbate plus Calcium Threonate)

Subconfluent monolayers of cell cultures, seeded in 24-well cluster plates, are supplemented with one-tenth volume

of working stock solutions to obtain final Test 1
concentration in the range 0.006 to 0.06% (corresponding to
0.28 mM-2.8mM ascorbic acid equivalents). Parallel sets of
wells are treated similarly with stock solutions of CA + CT
and CA alone, containing the same equivalents of AA as Test
1. Control cultures are treated with an equivalent volume
of sterile water. Periodic treatment with these
compositions is repeated at 1-2 day intervals by direct
addition of fresh solutions (without change of growth
medium).

Example 5

Assay of Cell Survival and Cell Death (Apoptosis)

Cell survival following treatment is assessed at
predetermined intervals by taking viable cell counts using a
Neubauer haemocytometer. Viable cells are scored as those
capable excluding trypan blue as previously described
(Harakeh and Jariwalla, Am.J.Clin.Nutr. 54:1231S-1235S
(1991)). The data are used to plot viable cell culture (#
of cells/ml) against the concentration of Test solutions to
evaluate the effect on cell survival.

The induction of apoptosis following treatment of various tumor cell types with the Test compositions and controls described in Example 1 is evaluated using an enzyme-linked immunoassay ("ELISA") developed by Boehringer-Mannheim (Indianapolis, IN). This assay specifically screens and detects histone-associated DNA complexes (nucleosomal fragments) appearing in the cytoplasm of treated cells relative to that in untreated controls. The presence and level of nucleosomal fragments in cytoplasmic lysates after different treatments is determined using the procedure specified in the cell-death detection ELISA kit, supplied by Boehringer-Mannheim.

Briefly, the ELISA assay is carried out as follows. At different intervals following treatment with the Test compositions, medium is aspirated and cell membranes are lysed by incubation with 200-500 μ L of lysis solution for 30 minutes at room temperature. Cell lysate is collected in an Eppendorf tube and centrifuged at 2500 rpm for 10 minutes to separate the nuclear fraction. An aliquot of the supernatant containing the cytoplasmic fraction is used to quantify the nucleosomal fragments by photometric detection at 410 nm in a micro plate reader. Data are processed as follows: The mean absorbance at 410 nm is plotted against

the concentration of the Test compound to compare the relative apoptosis-inducing doses determined for each treatment and compared. The minimal apoptosis-inducing dose is defined as that required to cause 2-fold change in apoptosis (i.e., nucleoprotein level) over that in the untreated control. Maximal apoptosis is defined as the maximal fold change in apoptosis over control.

TABLE 1
SUMMARY OF DATA

MINIMUM APOPTOTIC DOSE MAXIMUM FOLD INCREASE
IN APOPTOSIS

COMPOSITION	CELL LINE	DOSE CONC. (%)	# OF TREATMENTS	DOSE CONC. (%)	# OF TREATMENTS	MAXIMUM FOLD INCREASE IN APOPTOSIS
[Calcium Ascorbate + Metabolites]	Malme-3	0.025	2	0.033	2	3.58
	Malme-3M	0.006	1	0.025	2	116
	WRL-68	0.006-0.012	3	0.025	2	2.04
	SK-Hep-1	0.006	3	0.033	3	14.9
	SK-N-MC	0.008	2	0.033	4	13.6
	T-84	0.015	3	0.02-0.03	4	4
20						
[Calcium Ascorbate + Calcium Threonate]	Malme-3	0.025	2	0.025	2	2.16
	Malme-3M	0.012	2	0.025	2	65.7
	WRL-68	>0.05	3	0.0125	2	1.68
	SK-Hep-1	0.006	3	0.033	3	9.31
	SK-N-MC	0.015	4	0.033	4	7.02
	T-84	>0.06	3	0.033	3	1.5
Calcium Ascorbate	Malme-3	0.025	2	0.025	2	2.16
	Malme-3M	0.012	2	0.025	2	92.8
	WRL-68	0.012	3	0.012	3	2.22
	SK-Hep-1	0.006	3	0.033	3	12.04
	SK-N-MC	0.015	4	0.015	4	5.03
	T-84	>0.06	3	0.033	3	1.77

In Table 1, above, the "Minimum Apoptotic Dose" is the concentration of the Composition required to cause a 2-fold change in apoptosis over the control. The "Number of Treatments" is the total number of treatments with the Composition. The "Maximum Fold Increase in Apoptosis" is the maximal fold change in apoptosis over the control and the "Maximum Dose" is the concentration of the Composition which induces the "Maximum Fold Apoptosis" compared to the control.

CONCLUSIONS

The results of tests described above lead to the following conclusions:

The mineral ascorbate/vitamin C metabolite compositions illustrated by the Test 1 composition induce selective cell death (apoptosis) of diverse tumor cell-types in a dose-dependent fashion.

Mineral ascorbate/vitamin C metabolite compositions (as illustrated by the Test 1 composition) achieve apoptosis, i.e., minimum two-fold increase in cell death rate, at lower concentrations (AA equivalent) than is required to achieve such decrease with either mineral ascorbate alone (as

illustrated by the Test 2 composition) or with ascorbic acid alone.

The maximal level of apoptosis achievable with mineral ascorbate/vitamin C metabolite compositions (as illustrated by the Test 1 composition) against specific cell types, is higher than achievable with mineral ascorbate or ascorbic acid alone.

The AA equivalent concentration of mineral ascorbate/vitamin C metabolite compositions (as illustrated by the Test 1 composition) required to induce apoptosis in tumor cells is lower than for normal cells, and the magnitude of cell death in normal cells is considerably smaller than in tumor cells.

Treatment of cell cultures with ascorbic acid (AA) and/or calcium threonate (CT) (as illustrated in Example 2) produced selective dose-dependent cell death (apoptosis) in hepatoma and melanoma cells as compared to their respective normal cellular counterparts.

Pretreatment of hepatoma cells with CT followed by application of AA induced higher level of cellular apoptosis

than corresponding dose of AA or CT alone.

Having described the invention in such terms as to
enable those skilled in the art to understand and practice
it, and, having described the presently preferred embodiments
thereof, I CLAIM:

1. A selective chemotherapy method which includes the step of contacting tumor cells with a composition comprising:

(a) a plasma-soluble metal salt of ascorbic acid; and

(b) one or more vitamin C metabolites selected from the group consisting of

(i) aldonic acids, and the aldono-lactones, aldono-lactides and non-toxic metal salts thereof, and

(ii) dehydroascorbic acid, threose, erythreose, 4-hydroxy-5-methyl-3(2H)-furanone, 3-hydroxykojic acid and 5-hydroxymaltol.

2. A composition comprising the chemotherapeutic composition of Claim 1 in a pharmacologically acceptable intravenous carrier.

INTERNATIONAL SEARCH REPORT

International application No.
P S99/19449

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) :A61K 31/34

US CL :514/474

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/474

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

MEDLINE, HCAPLUS, USPATFULL- calcium ascorbate, ester-c and/or ascorbic acid metabolites for the treatment of tumors, cancers, neoplastic disease etc.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 4,822,816 A (MARKHAM) 18 April 1989(18/04/89), see entire document, especially col. 1, lines 25-34.	1-2
Y	US 5,626,883 A (PAUL) 06 May 1997(06/05/97), see entire document.	1-2
Y	US 5,869,116 A (YOO) 09 February 1999(09/02/99), see entire document, especially col. 8, lines 1-5.	1-2



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

03 JANUARY 2000

Date of mailing of the international search report

10 FEB 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

M. MOEZIE

Telephone No.

(703) 308-1235